drugset / Trial / NCT01772420
Phase II Study of Lenalidomide and Eltrombopag in Patients With Symptomatic Anemia
Phase 2
Completed
52 enrolled
Albert Einstein College of Medicine
National Cancer Institute (NCI) · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This phase II trial studies how well lenalidomide (LEN) and eltrombopag olamine (ELT) work in treating patients with symptomatic anemia in low or intermediate myelodysplastic syndrome (MDS). Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Eltrombopag olamine may increase the number of white blood cells and platelets found in bone marrow or peripheral blood. Giving lenalidomide and eltrombopag olamine may be an effective treatment for myelodysplastic syndrome.
Timeline
- Start
- 2012-10
- Primary completion
- 2020-07-09
- Completion
- 2020-07-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Eltrombopag | Small molecule | — | Oral |
| Subject | Lenalidomide | Other / unclassified | — | Oral |